Announcement • Jun 03
Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding On June 3, 2026, Thiogenesis Therapeutics, Corp. closed the oversubscription transaction. The company issued 18,143,700 common shares at an issue price of CAD 0.50 for gross proceeds of CAD 9,071,850. All securities issued in connection with the Offering are subject to a four-month plus one day hold period ending October 2, 2026. The Offering has received conditional acceptance from the TSX Venture Exchange and remains subject to final acceptance. In connection with the Offering, the Company paid certain qualified finders: (i) a cash finder's fee equal to 7% of the gross proceeds raised from subscribers introduced by such finders, and (ii) non-transferable finder's options equal to 7% of the Offered Shares issued to such subscribers. Each finder's option entitles the holder to acquire one common share at a price of CAD 0.60 per share for a period of three years. In total, the Company paid CAD 561,529.50 in finder's fees and issued 780,059 finder's options. An independent director of the Company participated in the Offering and acquired 150,000 Offered Shares. In connection with the Offering, the Company engaged Bloom Burton Securities Inc. as a financial and strategic advisor on a non-exclusive basis. Bloom Burton provided advisory services to the Company in respect of the oversubscribed Offering. The Company paid Bloom Burton Securities Inc. a cash fee of CAD 50,000 for its advisory services. Bloom Burton Securities Inc. does not own any securities of the Company. New Risk • May 27
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$227k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$227k). Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$31.1m market cap, or US$22.5m). Announcement • May 11
Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding Thiogenesis Therapeutics, Corp. announced a a non brokered private placement of up to 16,000,000 common shares of the Company at a price of CAD 0.50 per Common Share for gross proceeds of CAD 8,000,000 on May 11, 2026. This Offering is subject to the approval of the TSX Venture Exchange (the "Exchange"). The Company anticipates closing of the Offering by the end of May subject to receipt of al necessary regulatory approvals. Upon issuance, the Offered Shares will be subject to a four-month and one day hold period pursuant to securities laws in Canada and, where applicable, Exchange policies. In connection with the Offering, the Company may pay finder's fees to eligible persons in compliance with applicable securities laws and Exchange policies. 
